tetano
Editor, Senior Moderator
Emerg Infect Dis. 2010 Nov;16(11):1813-5.
Oseltamivir-Resistant Pandemic (H1N1) 2009 Treated with Nebulized Zanamivir.
Da Dalt L, Calistri A, Chillemi C, Cusinato R, Franchin E, Salata C, Sgarabotto D, Toscano G, Gambino A, Palu G.
University of Padova, Padova, Italy (L. Da Dalt, A. Calistri, C. Chillemi, E. Franchin, C. Salata, G. Palu); and Azienda Ospedaliera di Padova, Padova (R. Cusinato, E. Franchin, D. Sgarabotto, G. Toscano, A. Gambino).
Abstract
To the Editor: In late November 2009, a 3-year-old immunocompromised boy experienced an upper respiratory tract infection caused by influenza A pandemic (H1N1) 2009 virus, as demonstrated by a positive result for real-time PCR on a nasal swab specimen. His medical history was notable for a congenital intracardiac tumor; an ABO-incompatible heart transplant at 2 months of age; and an Epstein-Barr virus-related humoral rejection 20 months later that was treated with anti-CD20 and plasmapheresis and continuous immunosuppressive therapy with tacrolimus and everolimus. Thus, a 5-day regimen of oseltamivir treatment was undertaken, and the patient's clinical signs improved.
PMID: 21029559 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/21029559
Oseltamivir-Resistant Pandemic (H1N1) 2009 Treated with Nebulized Zanamivir.
Da Dalt L, Calistri A, Chillemi C, Cusinato R, Franchin E, Salata C, Sgarabotto D, Toscano G, Gambino A, Palu G.
University of Padova, Padova, Italy (L. Da Dalt, A. Calistri, C. Chillemi, E. Franchin, C. Salata, G. Palu); and Azienda Ospedaliera di Padova, Padova (R. Cusinato, E. Franchin, D. Sgarabotto, G. Toscano, A. Gambino).
Abstract
To the Editor: In late November 2009, a 3-year-old immunocompromised boy experienced an upper respiratory tract infection caused by influenza A pandemic (H1N1) 2009 virus, as demonstrated by a positive result for real-time PCR on a nasal swab specimen. His medical history was notable for a congenital intracardiac tumor; an ABO-incompatible heart transplant at 2 months of age; and an Epstein-Barr virus-related humoral rejection 20 months later that was treated with anti-CD20 and plasmapheresis and continuous immunosuppressive therapy with tacrolimus and everolimus. Thus, a 5-day regimen of oseltamivir treatment was undertaken, and the patient's clinical signs improved.
PMID: 21029559 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/21029559